Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “LIVER FUNCTION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1991

[The effect of partial splenic embolization (PSE) on liver function test in patients with liver cirrhosis].

Five patients with hypersplenism associated with liver cirrhosis were treated by PSE and the changes of peripheral blood cells and liver function tests were observed. After PSE, all patients had a high fever and abdominal pain continued for a few weeks without severe complications. Peripheral blood cell counts improved soon after PSE and liver function tests (hepaplastin test and ICGR15) grew transiently worse, but they also improved within two months. During 4.5 to 10 months, the levels of albumin and total cholesterol of three patients increased, although the changes of bilirubin level and HPT were not shown. For other two patients, it was difficult to estimate the effect of PSE, because one patient was treated at the same time with lipiodol chemoembolization for HCC and another patient had a progress of nephrotic syndrome. On the other hand, ICG levels were stable after PSE but RI-uptake on liver scintigram increased in the liver. These results suggest that PSE may be able to improve not only hypersplenism but also liver function in the patients with compensated liver cirrhosis without severe complication.

Blood Cell Count↗
PubMed1993

Comparison of in vivo and ex vivo porcine liver function using the same liver.

In vivo and ex vivo liver function was compared using the same livers to exclude interanimal variation in hepatic function. Six male pigs were anesthetized, and catheters and perivascular flow probes placed for transhepatic sampling and hepatic arterial and portal venous flow measurement. After a 2-h in vivo study period, the livers were resected and studied immediately afterwards for a further 2 h ex vivo as an isolated perfused preparation (Experiment A). Hepatic function in a further 6 pig livers (Experiment B) was studied ex vivo only for comparison with the ex vivo livers from Expt. A to determine whether the prior in vivo study had affected hepatic function. Despite using the same livers with similar total hepatic blood flows, (0.91 +/- 0.16 ml.g-1 x min-1) in vivo and (0.84 +/- 0.03 ml.g-1 x min-1) ex vivo, hepatic oxygen consumption (6.5 +/- 0.9 vs 2.6 +/- 0.2 ml O2 x 100 g-1), adenosine-5-triphosphate content (5.22 +/- 0.62 vs 4.14 +/- 0.71 microM.g liver-1) and bile flow (15.1 +/- 1.2 vs 6.0 +/- 1.0 ml.h-1) were initially less ex vivo and remained so throughout the study, while perfusate potassium (initially) (3.7 +/- 0.1 vs 6.4 +/- 0.3 meq.l-1), and aspartate aminotransferase (50 +/- 9 vs 76 +/- 5UL-1) was consistently higher than in vivo values. Initial hepatic energy charge (0.620 +/- 0.034 vs 0.552 +/- 0.061) and total adenine nucleotides 12.49 +/- 0.60 vs 11.66 +/- 0.62 microM.g liver-1) were not different and remained so subsequently.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenosine Diphosphate↗
PubMed2005

13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease.

BACKGROUND AND AIMS: Liver biopsy examination is the gold standard to diagnose the presence of cirrhosis. The aim of this study was to evaluate the accuracy of both 13 C-aminopyrine breath test ( 13 C-ABT) and 13 C-galactose breath test ( 13 C-GBT) in the noninvasive assessment of the presence of cirrhosis in patients with chronic liver disease. METHODS: We evaluated 61 patients with chronic liver disease of diverse etiologies (21 compensated cirrhosis). All patients underwent 13 C-GBT and 13 C-ABT, and the results were expressed as a percentage of the administered dose of 13 C recovered per hour (%dose/h) and as the cumulative percentage of administered dose of 13 C recovered over time (%dose cumulative). Results were analyzed according to absence vs presence of cirrhosis. RESULTS: On average, 13 C-GBT %dose/h and %dose cumulative were decreased significantly in patients with compensated cirrhosis, and the same finding was observed for 13 C-ABT results from 30 to 120 minutes. 13 C-GBT %dose/h at 120 minutes had 71.4% sensitivity, 85.0% specificity, and 83.7% accuracy, whereas 13 C-ABT %dose cumulative at 30 minutes had 85.7% sensitivity, 67.5% specificity, and 77.1% accuracy for distinguishing between the 2 subgroups of patients. Combined assessment of 13 C-GBT and 13 C-ABT increased the diagnostic accuracy (80% positive predictive value) of either test alone and reached 92.5% specificity and 100% sensitivity for the diagnosis of cirrhosis. CONCLUSIONS: In patients with chronic liver disease, both 13 C-GBT and 13 C-ABT are useful for the diagnosis of cirrhosis. Combination of the tests increases the diagnostic yield of each test alone.

Adult↗
PubMed1983

Cholic acid conjugation test and quantitative liver function in acute liver failure.

In 33 patients with acute hepatic encephalopathy due to toxic or viral hepatitis the following analyses were performed: (24-14C)cholic acid conjugation and sulfation, plasma phenazone clearance, galactose elimination capacity, and concentrations of glycocholic acid and glycolithocholic acid sulfate in plasma. The (24-14C)cholic acid conjugation in patients with viral hepatitis was significantly lower in fatal cases than in patients who survived (p less than 0.002). In these patients the galactose elimination capacity and the plasma phenazone clearance were insignificantly lower. Tauro-(24-14C)cholic acid was the predominant metabolite of (24-14C)cholic acid in six patients, but in four patients with toxic hepatitis this metabolite was only found in trace amounts. Sulfation after 3 h of (24-14C)cholic acid accounted for 0-8.2% of the administered dose. The sulfate of glycolithocholic acid was found in the plasma of all patients. No survival limit with regard to the capacity for the (24-14C)cholic acid conjugation could be defined.

Acute Disease↗
PubMed1988

[Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass].

Hepatic clearance of indocyanine green, a drug with a high hepatic extraction rate, and breath tests with aminopyrine, a drug with a low hepatic extraction ratio, were calculated in 26 patients with liver cirrhosis. In addition galactose elimination capacity was calculated as an index of functional liver cell mass. All these parameters resulted significantly correlated with each other. These results confirm the view that during liver cirrhosis, metabolism of drugs with high and low hepatic extraction rates can be described according to the intact hepatocyte theory.

Adult↗
PubMed2000

Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C.

Our aim was to compare color-coded Doppler sonography (CCDS) and quantitative testing of liver function (QTLF) in patients with chronic hepatitis C. In all, 74 patients with chronic hepatitis C and mild fibrosis underwent QTLF, which included aminopyrine breath test (ABT), galactose elimination capacity (GEC), sorbitol clearance (SC), and indocyanine green clearance (ICG). Hepatic artery velocity and resistance index (HA-V, HA-RI) as well as portal vein velocity (PV-V) were measured by CCDS. ABT, GEC, and PV-V were significantly reduced, whereas SC1, ICG, HA-V, and HA-RI showed normal levels. There was a significant correlation between reduction in PV-V only with GEC and ABT. QTLF did not correlate with HA-V and HA-RI. In conclusion, in hepatitis C patients with liver fibrosis, ABT and GEC are decreased significantly, which was paralleled by a reduction of PV-V. Unexpectedly SC1 and ICG, the classical hepatic perfusion parameters, do not correlate with the parameters measured by CCDS.

Aged↗
PubMed1983

Oral testosterone load related to liver function in men with alcoholic liver cirrhosis.

The relation between liver function and an oral testosterone load was examined in 42 consecutive patients with alcoholic liver cirrhosis. Administration of an oral load of 400 mg micronized free testosterone increased the serum concentration of testosterone (range, 31.9-694.4 nmol/l; median, 140.8 nmol/l) in male patients with alcoholic liver cirrhosis to significantly (P less than 0.01) higher levels than in male subjects without liver disease (range, 25.4-106.6 nmol/l; median, 61.5 nmol/l). The increase of testosterone after the load (log delta testosterone) in patients correlated inversely with galactose elimination capacity (r = 0.54; P less than 0.001), serum albumin (r = -0.53; P less than 0.001), plasma factor II + VII + X (r = 0.62; P less than 0.001), indocyanine green clearance (r = -0.71; P less than 0.001), and hepatic blood flow (r = -0.61; P less than 0.01) and correlated directly with wedged-to-free hepatic vein pressure (r = +0.54; P less than 0.01). The increase of testosterone after the load did not correlate significantly with sex hormone-binding globulin (r = +0.35; P greater than 0.05). It is concluded that the hepatic extraction of testosterone is significantly decreased in patients with alcoholic cirrhosis. This decrease seems to be due to decreased liver function, decreasing hepatic blood flow, and increased portosystemic shunting. Oral testosterone loading may therefore be of prognostic significance in patients with alcoholic liver cirrhosis.

Administration, Oral↗
PubMed1999

Use of Tc-99m DTPA galactosyl human serum albumin to predict postoperative residual liver function.

PURPOSE: Residual liver uptake at 15 minutes (RLU15), a new index for predicting residual liver function after excision of hepatocellular carcinoma, was evaluated using dynamic liver images and SPECT by Tc-99m DTPA galactosyl human serum albumin. MATERIALS AND METHODS: In 13 cases of hepatectomy, RLU15 was compared with postoperative serum prothrombin levels, serum bilirubin levels, and ascites. RESULTS: RLU15 showed good correlation with both the prothrombin activity and the serum bilirubin, with correlation coefficients of r = 0.829 and r = -0.757. CONCLUSION: This new index appears useful for predicting residual liver function after hepatectomy.

Ascites↗
PubMedDate not supplied

Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation.

BACKGROUND/AIMS: The liver plays a central role in the production and metabolism of lipoproteins, regulating their synthesis and degradation. The protein content of the lipoproteins are the so-called apolipoproteins. Some of the apolipoproteins serve as cofactors for enzymatic reactions, as ligands for interaction with specific receptors, and as structural proteins. Apolipoprotein B (apoB) is the primary structural component of the atherogenic low density lipoprotein (LDL) particles and has a specific binding region for interacting with the LDL-receptor. In contrast, apolipoprotein A-I (apoA-I) represents the primary protein content of the high density lipoprotein (HDL) particles, which interacts with the putative HDL-receptor, and stimulates the enzymatic reaction of lecithin-cholesterol acyltransferase (LCAT) resulting in esterified cholesterol, which is the essential step in the process of reverse cholesterol transport. METHODOLOGY: We studied lipid parameters in arterial and hepatic venous serum samples from 52 patients with cirrhosis and from 16 patients in the clinically stable long-term course after liver transplantation. Splanchnic blood flow was measured (indocyanine-green steady-state infusion) and hepatic extraction/production rates were calculated. To assess the influence of the clinical stage of established cirrhosis, the quantitated parameters were statistically analyzed. RESULTS: In cirrhosis, apolipoprotein A-I levels are decreased depending on the clinical stage (p<0.01). This parameter showed excellent correlations to liver function tests. Triglycerides (TG) (p<0.05) and cholesterol (Chol) (p<0.05) were reduced as well, whereas apolipoprotein B levels did not change. In cirrhosis, hepatic production of both cholesterol and triglycerides were decreased (p<0.05 each), as well as hepatic extraction of free fatty acids (FFA) (p<0.01). Except for cholestatic liver disease with raised serum cholesterol (p<0.05) and apolipoprotein B levels (p<0.001), the etiology of cirrhosis had no impact on the observed serum lipid alterations. CONCLUSIONS: The serum concentrations of the determined lipid parameters depend primarily on liver function. Decreased liver function was associated with reduced extraction of free fatty acids and reduced cholesterol and triglyceride synthesis. Liver transplantation restored the lipid abnormalities to normal. Finally, apolipoprotein A-I served as an excellent parameter for predicting liver function in the studied patients.

Apolipoproteins↗